The goal of pharmacogenetics is to deliver safe and effective drug therapy. Genetic polymorphisms in
cytochrome P450 (
CYP) enzyme genes are implicated in the inter-individual variability in pharmacokinetics of anti-epileptic drugs (AEDs). However, the clinical impact of
CYP polymorphisms on AED therapy remains controversial. Previous studies have shown that the defective
CYP2C9 alleles affect the required dose of phenytoin and the risk of its toxicity. We have reported that the
CYP2C19-deficient genotype is associated with the serum concentration of an active metabolite of clobazam,
N-desmethylclobazam, and with the clinical efficacy of clobazam therapy. We determined also the influence of polymorphisms in
CYP genes on the population pharmacokinetic parameters of AEDs using a non-linear mixed effect modeling program, which enables us to define relevant genetic factors together with other factors, and the magnitude of the effect on variation in pharmacokinetics in patients. The defective alleles of
CYP2C9 and
CYP2C19 were found to have significant effects on the inter-individual differences in clearance of phenobarbital and zonisamide, respectively. Based on these recent findings, we discuss the clinical significance of AED dose adjustment according to both genetic and non-genetic factors that affect CYP activity.
抄録全体を表示